Background: Cervical cancer remains a significant public health concern in Macao SAR despite the implementation of a cervical cancer screening program and HPV vaccination. To improve early detection, Macao SAR introdu...Background: Cervical cancer remains a significant public health concern in Macao SAR despite the implementation of a cervical cancer screening program and HPV vaccination. To improve early detection, Macao SAR introduced HPV DNA testing alongside cytology (co-testing) as the primary screening method in 2019. This study evaluates the effectiveness of co-testing in identifying cervical precancerous lesions (CIN2+) compared to cytology alone. Methods: We conducted a retrospective analysis of women aged 30 - 65 years who participated in the routine cervical cancer screening program in Macao SAR Primary Healthcare Centers from 2019 to 2022. Data from over 70,000 women were analyzed, comparing the detection rates of CIN2+ through co-testing and cytology alone. Women with abnormal cytology or positive HPV results were referred for colposcopy. Results: The introduction of co-testing led to a significant increase in the detection of CIN2+, particularly in women with atypical squamous cells of undetermined significance (ASCUS) or negative for intraepithelial lesion or malignancy (NILM) cytology results. Between 2019 and 2022, the percentage of women with ASCUS/NILM and any high-risk HPV (hrHPV) positive who were diagnosed with CIN2+ after colposcopy were 24%, 13%, 10% and 7.5% respectively. This highlights the ability of co-testing to identify high-risk individuals who would have been missed by cytology alone. Discussion: Our findings demonstrate the effectiveness of co-testing in improving the sensitivity of cervical cancer screening in Macao SAR. The inclusion of HPV DNA testing allows for better risk stratification of women with ASCUS/NILM cytology, leading to more targeted referrals for colposcopy and timely detection of precancerous lesions. The initial high positive rate in 2019 (24%) might be attributed to the small sample size and potentially reflects a backlog of undiagnosed cases prior to co-testing implementation. Conclusion: The implementation of co-testing in Macao SAR’s cervical cancer screening program significantly improves the early detection of precancerous lesions, particularly in women with ambiguous cytology results. This proactive approach contributes to reducing cervical cancer morbidity and mortality and improving women’s health outcomes in Macao SAR.展开更多
Objective: This study aims to explore the correlation between human papillomavirus (HPV) and Mycoplasma genitalium (CT) combined with TCT detection in cervical cancer screening. Method: A cross-sectional study design ...Objective: This study aims to explore the correlation between human papillomavirus (HPV) and Mycoplasma genitalium (CT) combined with TCT detection in cervical cancer screening. Method: A cross-sectional study design was adopted, and a total of 609 women who came to seek medical treatment were recruited as the study subjects. Combination testing was evaluated on cervical cancer screening by testing the women for HPV, CT with TCT detection and analyzing the relationship of cervical lesions with HPV and CT infection. Results: The study results showed that 21.57% of the subjects were infected with both HPV and CT, and 48.42% of the cases had abnormal TCT results at the same time. Further data analysis showed that HPV infection was significantly associated with abnormal TCT outcomes (p < 0.05), suggesting a possible synergistic effect of the two infections in cervical lesions. The combined sensitivity and specificity of HPV, CT and TCT detection were 21.57% and 48.42%, respectively, which were significantly higher than that of single detection. Conclusion: In summary, the results of this study support the importance of combined HPV, CT, and TCT testing in cervical cancer screening, and propose the hypothesis that combined testing may improve screening effectiveness. However, further large sample studies are needed to confirm this conclusion and explore the prospects of combined testing in clinical practice.展开更多
目的：评价高危型人乳头瘤病毒（HPV DNA）与液基细胞学检测（TCT）在宫颈疾病筛查中的应用价值。方法收集2012年10月—2013年12月某院妇科宫颈病变就诊患者的标本进行 HPV DNA 分型和 TCT 检测，阳性者进行阴道镜病理学检测，比较各 T...目的：评价高危型人乳头瘤病毒（HPV DNA）与液基细胞学检测（TCT）在宫颈疾病筛查中的应用价值。方法收集2012年10月—2013年12月某院妇科宫颈病变就诊患者的标本进行 HPV DNA 分型和 TCT 检测，阳性者进行阴道镜病理学检测，比较各 TCT 组、不同病变类型患者 HPV DNA 阳性率，比较 TCT 和 HPV DNA 检测的灵敏度和特异性，二者单独与联合检测的差异。结果HPV DNA 阳性率为28．07％（1045／3723），以高危型（HR）－HPV 为主，阳性率为21．57％（803例），最常见的 HR-HPV DNA 基因型为 HPV16、58、52、18型。各年龄组 HR－HPV 阳性率比较，差异有统计学意义（χ^2＝31．74，P ＜0．001），其中20～30岁年龄组阳性率最高。TCT阳性率为13．46%（501例），共971例患者进行病理检测，293例病理诊断阳性。按 TCT 和不同病变类型分组，将HR-HPV DNA 阳性率进行趋势χ2检验，结果均显示随病变程度增加，HR-HPV 阳性率呈增高趋势（均 P ＜0．01）。以病理诊断作为金标准，HR-HPV DNA 和 TCT 灵敏度分别为90．44％（265／293）、85．32％（250／293），两者联合检测灵敏度为95．90％。病理阳性者中，TCT 和 HPV DNA 检出率分别为85．32％、90．44％，联合检测检出率为95．90％，3组比较，差异有统计学意义（χ^2＝18．185，P ＜0．001）。其中联合检测检出率高于单独使用 TCT、HPV DNA。结论HPV DNA 检测对宫颈癌筛查是一个有益的补充，HPV DNA 联合 TCT 检测可以最大限度地降低漏诊率。展开更多
文摘Background: Cervical cancer remains a significant public health concern in Macao SAR despite the implementation of a cervical cancer screening program and HPV vaccination. To improve early detection, Macao SAR introduced HPV DNA testing alongside cytology (co-testing) as the primary screening method in 2019. This study evaluates the effectiveness of co-testing in identifying cervical precancerous lesions (CIN2+) compared to cytology alone. Methods: We conducted a retrospective analysis of women aged 30 - 65 years who participated in the routine cervical cancer screening program in Macao SAR Primary Healthcare Centers from 2019 to 2022. Data from over 70,000 women were analyzed, comparing the detection rates of CIN2+ through co-testing and cytology alone. Women with abnormal cytology or positive HPV results were referred for colposcopy. Results: The introduction of co-testing led to a significant increase in the detection of CIN2+, particularly in women with atypical squamous cells of undetermined significance (ASCUS) or negative for intraepithelial lesion or malignancy (NILM) cytology results. Between 2019 and 2022, the percentage of women with ASCUS/NILM and any high-risk HPV (hrHPV) positive who were diagnosed with CIN2+ after colposcopy were 24%, 13%, 10% and 7.5% respectively. This highlights the ability of co-testing to identify high-risk individuals who would have been missed by cytology alone. Discussion: Our findings demonstrate the effectiveness of co-testing in improving the sensitivity of cervical cancer screening in Macao SAR. The inclusion of HPV DNA testing allows for better risk stratification of women with ASCUS/NILM cytology, leading to more targeted referrals for colposcopy and timely detection of precancerous lesions. The initial high positive rate in 2019 (24%) might be attributed to the small sample size and potentially reflects a backlog of undiagnosed cases prior to co-testing implementation. Conclusion: The implementation of co-testing in Macao SAR’s cervical cancer screening program significantly improves the early detection of precancerous lesions, particularly in women with ambiguous cytology results. This proactive approach contributes to reducing cervical cancer morbidity and mortality and improving women’s health outcomes in Macao SAR.
文摘Objective: This study aims to explore the correlation between human papillomavirus (HPV) and Mycoplasma genitalium (CT) combined with TCT detection in cervical cancer screening. Method: A cross-sectional study design was adopted, and a total of 609 women who came to seek medical treatment were recruited as the study subjects. Combination testing was evaluated on cervical cancer screening by testing the women for HPV, CT with TCT detection and analyzing the relationship of cervical lesions with HPV and CT infection. Results: The study results showed that 21.57% of the subjects were infected with both HPV and CT, and 48.42% of the cases had abnormal TCT results at the same time. Further data analysis showed that HPV infection was significantly associated with abnormal TCT outcomes (p < 0.05), suggesting a possible synergistic effect of the two infections in cervical lesions. The combined sensitivity and specificity of HPV, CT and TCT detection were 21.57% and 48.42%, respectively, which were significantly higher than that of single detection. Conclusion: In summary, the results of this study support the importance of combined HPV, CT, and TCT testing in cervical cancer screening, and propose the hypothesis that combined testing may improve screening effectiveness. However, further large sample studies are needed to confirm this conclusion and explore the prospects of combined testing in clinical practice.
文摘目的：评价高危型人乳头瘤病毒（HPV DNA）与液基细胞学检测（TCT）在宫颈疾病筛查中的应用价值。方法收集2012年10月—2013年12月某院妇科宫颈病变就诊患者的标本进行 HPV DNA 分型和 TCT 检测，阳性者进行阴道镜病理学检测，比较各 TCT 组、不同病变类型患者 HPV DNA 阳性率，比较 TCT 和 HPV DNA 检测的灵敏度和特异性，二者单独与联合检测的差异。结果HPV DNA 阳性率为28．07％（1045／3723），以高危型（HR）－HPV 为主，阳性率为21．57％（803例），最常见的 HR-HPV DNA 基因型为 HPV16、58、52、18型。各年龄组 HR－HPV 阳性率比较，差异有统计学意义（χ^2＝31．74，P ＜0．001），其中20～30岁年龄组阳性率最高。TCT阳性率为13．46%（501例），共971例患者进行病理检测，293例病理诊断阳性。按 TCT 和不同病变类型分组，将HR-HPV DNA 阳性率进行趋势χ2检验，结果均显示随病变程度增加，HR-HPV 阳性率呈增高趋势（均 P ＜0．01）。以病理诊断作为金标准，HR-HPV DNA 和 TCT 灵敏度分别为90．44％（265／293）、85．32％（250／293），两者联合检测灵敏度为95．90％。病理阳性者中，TCT 和 HPV DNA 检出率分别为85．32％、90．44％，联合检测检出率为95．90％，3组比较，差异有统计学意义（χ^2＝18．185，P ＜0．001）。其中联合检测检出率高于单独使用 TCT、HPV DNA。结论HPV DNA 检测对宫颈癌筛查是一个有益的补充，HPV DNA 联合 TCT 检测可以最大限度地降低漏诊率。
